Abstract 1142: Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020

Elizabeth Budde, MD PhD, Ajay K. Gopal, MD, Ian W. Flinn, MD, PhD, Loretta J. Nastoupil, MD, Michael S. Gordon, MD, Ching-Fai Pang, PhD, Bruce Keyt, PhD, Steve Carroll, PhD, Maya Leabman, PhD, Genevive Hernandez, PhD, Iris Sison, Daniel Chen, MD, PhD, Wayne Godfrey, MD and Philippe Armand, MD, PhD

IGM Biosciences, Inc., 325 E Middlefield Road, Mountain View, CA 94043

ASH 2020 Abstract 1142 IGM-2323 Budde et al

Posted in publications.